Skip to main content
Top
Published in:

Open Access 09-05-2024 | Cytokines | REVIEW

Tumor Necrosis Factor and Interleukin Modulators for Pathologic Pain States: A Narrative Review

Authors: Alan D. Kaye, Dominique M. Perilloux, Alison M. Hawkins, Grace C. Wester, Amanda R. Ragaland, Sage V. Hebert, Julian Kim, Michael Heisler, Rucha A. Kelkar, Azem A. Chami, Sahar Shekoohi, Adam M. Kaye

Published in: Pain and Therapy | Issue 3/2024

Login to get access

Abstract

Chronic pain, a complex and debilitating condition, involves intricate interactions between central and peripheral inflammatory processes. Cytokines, specifically tumor necrosis factor (TNF) and interleukins (IL), are key mediators in the initiation and maintenance of chronic pain states. Sensory neurons expressing receptors for cytokines like TNF, IL-1, and IL-6 are implicated in peripheral sensitization, contributing to increased signaling of painful sensations. The potential of targeting TNF and IL for therapeutic intervention in chronic pain states is the focus of this review, with preclinical and clinical evidence supporting the use of TNF and IL modulators for pain management. The physiological and pathological roles of TNF in neuropathic pain is complex. Experimental evidence highlights the effectiveness of TNF modulation in mitigating pain symptoms in animal models and displays promising outcomes of clinical trials with TNF inhibitors, such as infliximab and etanercept. ILs, a diverse group of cytokines, including IL-1, IL-6, and IL-17, are discussed for their contributions to chronic pain through inflammation and peripheral sensitization. Specific IL modulators, such as secukinumab and tocilizumab, have shown potential in managing chronic neuropathic pain, as demonstrated in various studies and clinical trials. The pharmacokinetics, safety profiles, and challenges associated with TNF and IL modulators highlight the need for cautious medication monitoring in clinical practice. Comparative evaluations have revealed distinct efficacy and safety profiles among different cytokine modulators, emphasizing the need for personalized approaches based on the specific underlying causes of pain. Further research is necessary to elucidate the intricate mechanisms by which cytokines contribute to chronic pain, as well as to understand why they may affect pain differently in various contexts. Additionally, long-term safety profiles of cytokine modulators require more thorough investigation. This continued exploration holds the promise of enhancing our comprehension of cytokine modulation in chronic pain and shaping more potent therapeutic strategies for the future.
Literature
25.
go back to reference Richter F, Natura G, Ebbinghaus M, von Banchet GS, Hensellek S, König C, et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 2012;64(12):4125–34. https://doi.org/10.1002/art.37695.CrossRefPubMed Richter F, Natura G, Ebbinghaus M, von Banchet GS, Hensellek S, König C, et al. Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents. Arthritis Rheum. 2012;64(12):4125–34. https://​doi.​org/​10.​1002/​art.​37695.CrossRefPubMed
31.
go back to reference Sainoh T, Orita S, Miyagi M, Sakuma Y, Yamauchi K, Suzuki M, et al. Interleukin-6 and interleukin-6 receptor expression, localization, and involvement in pain-sensing neuron activation in a mouse intervertebral disc injury model. J Orthop Res. 2015;33(10):1508–14. https://doi.org/10.1002/jor.22925.CrossRefPubMed Sainoh T, Orita S, Miyagi M, Sakuma Y, Yamauchi K, Suzuki M, et al. Interleukin-6 and interleukin-6 receptor expression, localization, and involvement in pain-sensing neuron activation in a mouse intervertebral disc injury model. J Orthop Res. 2015;33(10):1508–14. https://​doi.​org/​10.​1002/​jor.​22925.CrossRefPubMed
33.
go back to reference An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents - Donnelly - 2009 - Annals of the New York Academy of Sciences - Wiley Online Library [Internet]. [cited 2024 Jan 26]. Available from: https://nyaspubs.onlinelibrary.wiley.com/doi/https://doi.org/10.1111/j.1749-6632.2009.05382.x An Overview of Cytokines and Cytokine Antagonists as Therapeutic Agents - Donnelly - 2009 - Annals of the New York Academy of Sciences - Wiley Online Library [Internet]. [cited 2024 Jan 26]. Available from: https://​nyaspubs.​onlinelibrary.​wiley.​com/​doi/​https://​doi.​org/​10.​1111/​j.​1749-6632.​2009.​05382.​x
43.
go back to reference Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, et al. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study. Ther Adv Musculoskelet Dis. 2019;5(11):1759720X19831151. https://doi.org/10.1177/1759720X19831151.CrossRef Bessette L, Haraoui B, Chow A, Fortin I, Dixit S, Khraishi M, et al. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study. Ther Adv Musculoskelet Dis. 2019;5(11):1759720X19831151. https://​doi.​org/​10.​1177/​1759720X19831151​.CrossRef
44.
go back to reference Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37. https://doi.org/10.1002/art.39093.CrossRefPubMed Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424–37. https://​doi.​org/​10.​1002/​art.​39093.CrossRefPubMed
Metadata
Title
Tumor Necrosis Factor and Interleukin Modulators for Pathologic Pain States: A Narrative Review
Authors
Alan D. Kaye
Dominique M. Perilloux
Alison M. Hawkins
Grace C. Wester
Amanda R. Ragaland
Sage V. Hebert
Julian Kim
Michael Heisler
Rucha A. Kelkar
Azem A. Chami
Sahar Shekoohi
Adam M. Kaye
Publication date
09-05-2024
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 3/2024
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-024-00603-8

Other articles of this Issue 3/2024

Pain and Therapy 3/2024 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare